Brokerages Set Novo Nordisk A/S (NYSE:NVO) Target Price at $65.56

Novo Nordisk A/S (NYSE:NVO) has received an average rating of “Hold” from the twenty analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $64.9375.

A number of equities research analysts have weighed in on the company. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk CEO Mike Doustdar said demand for weight-loss medicines still has a “long runway,” arguing that GLP-1 adoption remains in its early stages and could ultimately reduce healthcare costs and improve productivity. Novo Nordisk CEO sees long runway for weight-loss drugs
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, expanding the company’s diabetes portfolio and providing a potential new commercial growth driver beyond obesity treatments. Awiqli now available in the US
• Positive Sentiment: Erste Group raised its 2026 earnings-per-share estimate for Novo Nordisk to $3.27 from $3.20, while bullish commentary argues that the company’s broader cardiometabolic pipeline is being undervalued. Analysts raise Novo Nordisk earnings estimates
• Neutral Sentiment: Novo Nordisk is suing Eli Lilly over weight-loss-drug advertising. Management says the lawsuit is intended to ensure fair competition, but the dispute also highlights the intensifying rivalry between the two leading obesity-drug companies. Novo Nordisk CEO defends lawsuit against Eli Lilly
• Negative Sentiment: Analysts cited flat Wegovy sales, pricing challenges, pipeline setbacks and the risk that Eli Lilly is pulling ahead in the oral obesity market. These concerns, combined with the Berenberg downgrade, are weighing on sentiment toward NVO. Berenberg cuts Novo Nordisk as Lilly takes the oral market

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors have recently added to or reduced their stakes in the stock. Somerville Kurt F purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $231,000. Trust Co. of Vermont purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $1,250,000. Platform Technology Partners grew its stake in shares of Novo Nordisk A/S by 39.2% in the 2nd quarter. Platform Technology Partners now owns 10,941 shares of the company’s stock valued at $525,000 after purchasing an additional 3,079 shares during the last quarter. Fortis Group Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 145.5% in the second quarter. Fortis Group Advisors LLC now owns 72,916 shares of the company’s stock valued at $3,496,000 after purchasing an additional 43,213 shares during the period. Finally, Allen Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth approximately $205,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.4%

NVO opened at $46.52 on Thursday. The business’s 50-day simple moving average is $47.24 and its 200-day simple moving average is $44.61. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The stock has a market capitalization of $207.71 billion, a P/E ratio of 11.37, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Analysts anticipate that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be issued a $0.5786 dividend. This represents a dividend yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is presently 42.79%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.